Patents by Inventor Robert Davis

Robert Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Wire bundle fitting test apparatus, system and method therefor
    Patent number: 10942082
    Abstract: A leak test apparatus including a sleeve member having a first end and a second end and being configured to surround a portion of a transmission medium, a first retaining device configured to couple the first end of the sleeve member to a boundary fitting to which the transmission medium is coupled, and where the sleeve member is configured to contain a leak detection medium and effect a pressurization of the boundary fitting with the leak detection medium.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 9, 2021
    Assignee: The Boeing Company
    Inventors: Travis E. Dreyfoos, Kane M. Mordaunt, Robert Davis
  • NOVEL METHODS
    Publication number: 20210060009
    Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.
    Type: Application
    Filed: March 15, 2019
    Publication date: March 4, 2021
    Inventors: Gretchen SNYDER, Robert DAVIS, Lawrence P. WENNOGLE
  • ORGANIC COMPOUNDS
    Publication number: 20210060010
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: September 9, 2020
    Publication date: March 4, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(6Br,10aS)-3-METHYL-2, 3, 6b, 9, 10, 10a-HEXAHYDRO-1H, 7H-PYRIDO[3', 4', 5] PYROLO[1,2,3-de] QUINOXALIN-8YL)- 1- (4-FLUOROPHENYL)-BUTANE-1-ONE AND METHODS OF TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM
    Publication number: 20210032247
    Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 4, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Qiang ZHANG, Robert DAVIS, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 10906906
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, the compounds of formula I: in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of central nervous system (CNS) diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 2, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert Davis
  • Organic compounds
    Patent number: 10899762
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: January 26, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • ORGANIC COMPOUNDS
    Publication number: 20210008065
    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 14, 2021
    Inventors: Peng LI, Robert DAVIS
  • ORGANIC COMPOUNDS
    Publication number: 20210009592
    Abstract: The invention relates to particular deuterated substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 14, 2021
    Inventors: Peng LI, Qiang ZHANG, Robert DAVIS
  • NOVEL METHODS
    Publication number: 20210000822
    Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
    Type: Application
    Filed: July 7, 2020
    Publication date: January 7, 2021
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • NOVEL METHODS
    Publication number: 20210002280
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: January 7, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • NOVEL METHODS
    Publication number: 20200407362
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
    Type: Application
    Filed: July 10, 2020
    Publication date: December 31, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • METHODS OF TREATING CANCER WITH PLK4 INHIBITORS
    Publication number: 20200383990
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Application
    Filed: December 6, 2018
    Publication date: December 10, 2020
    Inventors: Karen Oegema, Andrew Shiau, Arshad Desai, Franz Meitinger, Robert Davis
  • NOVEL COMPOSITIONS AND METHODS
    Publication number: 20200375988
    Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 3, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Wei YAO, Robert DAVIS
  • Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system
    Patent number: 10844061
    Abstract: The invention relates to pharmaceutical compositions comprising compounds of Formula Q: wherein W is N(H)—, or —N(CH3)—, and Y is —C(?O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 24, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Qiang Zhang, Robert Davis, Lawrence P. Wennogle
  • Organic compounds
    Patent number: 10799500
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: October 13, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Amplified ballistic separator for separating material
    Patent number: 10792705
    Abstract: A novel ballistic separator for separating material is disclosed that includes a separator bed adapted to contact the material. The bed has a first agitator with a top surface, with the top surface comprising a conveyor connected to the first agitator. A crankshaft imparts an oscillating motion to the first agitator and conveyor, which move fixed together relative to the oscillating motion. The conveyor is constructed to move laterally across to the top surface.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: October 6, 2020
    Assignee: CP Manufacturing, Inc.
    Inventors: Nicholas Davis, Robert Davis
  • NOVEL METHODS
    Publication number: 20200306247
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Robert DAVIS
  • LIQUID CRYSTAL WAVEGUIDE WITH SUB-APERTURE LIGHT COUPLING
    Publication number: 20200301240
    Abstract: A Liquid Crystal Waveguide (LCW) system can provide sub-aperture incoupling or outcoupling of light having an input wavelength and input beamsize defining an aperture characteristic of the system. A Liquid Crystal Waveguide (LCW) can include a generally planar LCW core to receive light via a light input zone for communication toward a light output zone. Sub-aperture interfacial light couplers can be planarly arranged in or parallel to the planar LCW core in the light input zone or the light output zone. Sub-aperture interfacial light couplers can include teeth, prisms, or facets, a photonic crystal metasurface, or a geometric-phased holograph (GPH)). Overall LCW thickness can be reduced, which can be helpful in space-limited applications or for reducing material costs.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 24, 2020
    Inventors: Michael Ziemkiewicz, Michael Howard Anderson, Tyler Adam Dunn, David Edward Fish, Scott Dennis Rommel, Andrew William Sparks, Scott Robert Davis
  • NOVEL USES
    Publication number: 20200289519
    Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 17, 2020
    Inventors: David KASS, Toru HASHIMOTO, Lawrence P. WENNOGLE, Joseph HENDRICK, Robert DAVIS
  • AMPLIFIED BALLISTIC SEPARATOR FOR SEPARATING MATERIAL
    Publication number: 20200282428
    Abstract: A novel ballistic separator for separating material is disclosed that includes a separator bed adapted to contact the material. The bed has a first agitator with a top surface, with the top surface comprising a conveyor connected to the first agitator. A crankshaft imparts an oscillating motion to the first agitator and conveyor, which move fixed together relative to the oscillating motion. The conveyor is constructed to move laterally across to the top surface.
    Type: Application
    Filed: December 21, 2019
    Publication date: September 10, 2020
    Inventors: Nicholas Davis, Robert Davis